EVElena I. Veselova

Elena I. Veselova

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Elena I. Veselova has a total of 56 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Treatment of disseminated mycobacteriosis caused by Mycobacterium avium in HIV patients using bedaquiline: clinical examples

    by E.I. Veselova, E.N. Kuznetsova, D.I. Zilfova, A.B. Peregudova, V.V. Tinkova, I.A. Vasilieva

    Three clinical cases of treatment of patients with disseminated mycobacteriosis caused by M. avium using the drug bedaquilin have been described. The criteria for prescribing bedaquiline were M. avium resistance to two drugs in the regimen (primarily to clarithromycin) and/or adverse events leading to drug withdrawal. Regimen of the bedaquiline administration: 400 mg once daily for the first 14 days, from day 15 until the end of the course of therapy – 200 mg 3 times a week. The main criteria for treatment efficacy were: normalization of temperature, relief of clinical manifestations, cessation of isolation of nontuberculous mycobacteria. All patients had involvement of the intra-abdominal lymph nodes, lungs, and intestines. There was also involvement of the intrathoracic lymph nodes, peripheral lymph nodes, and bone marrow. Duration of the bedaquiline therapy ranged from 14 to 17 months and depended on the timing of the cessation of bacterial excretion. During the bedaquiline therapy there was no adverse events that required discontinuation of the drug. Upon completion of therapy no relapses were recorded during 2 years observation. We conclude, that use of bedaquiline in the treatment regimens of disseminated mycobacteriosis caused by M. avium in HIV-infected patients helped to stabilize the condition, the cessation of bacterial excretion and improve immunological parameters, including an increase in CD4 T-lymphocyte count. The results obtained require further study of the use of bedaquiline in this category of patients.

  • Open Access

    Molecular and genetic features of pathogens in patients with unfavorable course of tuberculosis and HIV infection

    by Elena I. Veselova, A.B. Peregudova, V.V. Tinkova, Anastasia V. Fedorova, O.V. Lovacheva, A.A. Kazyulina, A.G. Samoylova

    Objective. To study molecular and genetic features of M. tuberculosis (MTB) and human immunodeficiency virus (HIV) in patients with unfavorable course of HIV infection and tuberculosis. Materials and Methods. A total of 105 patients with HIV infection and newly diagnosed tuberculosis in whom tuberculosis was confirmed by microbiological and molecular genetic methods were included. The follow-up period was at least 6 months. Based on the results of the examination during treatment, all patients were divided into two groups: group 1 – patients with favorable course of HIV infection and tuberculosis (n = 78), group 2 – patients with unfavorable course of HIV infection and tuberculosis (n = 27). The study analyzed molecular and genetic features of HIV and MTB in patients with unfavorable/favorable course of HIV infection and tuberculosis. Results. In patients with an unfavorable course of HIV infection and tuberculosis (group 2), the frequency of detection of drug resistance mutations in the DNA of MTB was higher and the number of drugs to which mutations were present was greater than in patients with a favorable course of HIV infection and tuberculosis (group 1) (p = 0.030 and 0.019, respectively). The spectrum of drug resistance mutations was more diverse. Also, mutations of drug resistance to antiretroviral drugs (p = 0.042) were detected more often in HIV in group 2 patients, including to antiretroviral drugs of the non-nucleoside reverse transcriptase inhibitors and protease inhibitors classes, which pose high risk of antiretroviral therapy failure. Conclusions. In patients with HIV/TB unfavorable course, both MTB and HIV studies are required to identify mutations of drug resistance and prescribe treatment regimens based on the resistance profile. The optimal solution is to determine resistance profile before starting HIV/TB treatment, which requires a powerful laboratory base.

  • Open Access

    Factors Predicting an Unfavorable Course in the Patients with TB/HIV Co-infection

    by E. I. Veselova, A. B. Peregudova, В. В. Тинькова, T. E. Tyulkova, O. V. Lovacheva, A. G. Samoylova

    The objective : to identify early factors of unfavorable course of TB/HIV co-infection in order to improve approaches to treatment of such patients. Subjects and Methods . The study included 105 HIV-positive patients diagnosed with tuberculosis for the first time and M.tuberculosis (MTB) DNA was detected in a biological sample by a molecular genetic test. Patients were divided into two groups: a group with a favorable course of TB/HIV co-infection (78 people) and a group with an unfavorable course (27 people). Results. Significant factors influencing the course of TB/HIV co-infection and easily assessible in each patient (levels of leukocyte (x), hemoglobin (y), albumin (z), and iron (w)) were identified. A discriminant model was developed representing formula D = -8.263-0.110x + 0.012y + 0.197z + 0.024w. The accuracy of the model is 83.3%. If this parameter D ≥ -0.301, then a patient has a low risk of an unfavorable course of the co-infection; if D < -0.301, a patient faces a high risk of an unfavorable course of TB/HIV co-infection. In case of an unfavorable prognosis, an extended molecular genetic testing of M. tuberculosis drug susceptibility will allow choosing an adequate anti-tuberculosis treatment regimen. If no data about M. tuberculosis are available, treatment regimens for drug-resistant tuberculosis should be used.

  • Open Access

    Characteristics of Isolated Pulmonary and Generalized Mycobacteriosis in HIV-Positive Patients

    by E. I. Veselova, O. V. Lovacheva, A. B. Peregudova, A. A. Kazyulina

    The objective : to analyze and compare laboratory parameters in isolated pulmonary and generalized mycobacteriosis in HIV-positive patients. Subjects and Methods . 115 adult HIV-positive patients with mycobacteriosis were included in a retrospective study, they all underwent in-patient treatment in Infectious Diseases Department of National Medical Research Center of Phthisiopulmonology and Infectious Diseases from 2019 to 2022. All patients included in the study had mycobacteriosis caused by Mycobacterium avium . Results . Of the 115 patients, 70 (60.9%) were diagnosed with generalized mycobacteriosis (GM), and 45 (39.1%) were diagnosed with isolated pulmonary mycobacteriosis (IPM). In GM, there were no patients with a CD4+ T count greater than 85 cells/μl, and 75% of them had the count below 29.0 cells/μl. In IPM, the maximum CD4+ T count was 684 cells/μl, and 75% of patients had this count above 54.5 cells/μl. In GM versus IPM, the median CD4+ count was 10 times lower (13 cells/μl versus 134 cells/μl), and the mean VL in patients who did not receive ART or received ART for less than 2 months was higher (4.76 versus 3.91 log10 HIV RNA copies/ml; p = 0.006). In GM Group, the most frequent (77.2%) combination was the following: CD4+ 0-50 cells/μl with VL 100,000 copies/ml (in 48.6% of patients) and CD4+ 0-50 cells/μl with VL 1001-99,999 copies/ml (in 28.6% of patients). In IPM Group, the most frequent (48.9%) combination was the following: CD4+ >200 cells/μl with VL 1000 copies/ml and below (28.9%) and with CD4+ 101-200 cells/μl with VL 1000 copies/ml and below – in 20.0% of patients). With CD4+ >101 cells/μl, even a high VL (100,000 copies/ml and above) did not lead to generalization of mycobacteriosis.

  • Open Access

    Generalized Mycobacteriosis in HIV Patients

    by E. I. Veselova, E. N. Kuznetsova, A. B. Peregudova, В. В. Тинькова, A. A. Kazyulina, I. A. Vasilyeva

    The objective: to evaluate clinical, laboratory and instrumental signs of generalized mycobacteriosis (MB) in HIV patients.Subjects and Methods. Generalized MB was diagnosed in 83 patients with HIV, patients. 57.8% (48 people) were men, while 42.2% (35 people) were women. The average age of patients was 39.2 years (from 19 to 63 years).Results. The M. avium complex was the main etiological agent of generalized MB in HIV patients (97.6%). The most frequent clinical manifestations included fever (80/83 (96.1%)); abdominal discomfort and pain, diarrhea (53/83 (63.8%)), and decreased body weight (56/83 (67%)). The median CD4+ count in the group was 50 cells/μL. In 52% (43/83) of cases, generalized MB developed concurrently with other opportunistic or secondary infections (CMVI, pneumocystis pneumonia, and candidiasis). In 70% of cases (55/78), NTMs were isolated from two or more biological specimens. The positive result of blood culture for NTM had the greatest clinical significance (in 32/60 (53%) of the examined patients).


  • Open Access

    A Predictive Model of the HIV Infection Course

    by E. I. Veselova, G. D. Kaminskiy, K. A. Kocharyan, A. B. Peregudova, O. V. Lovacheva, A. G. Samoylova

    The course of HIV infection depends on the degree of HIV suppression during ART.The objective: to evaluate feasibility of using three factors: viral load (VL), HIV reservoir and CD8 T cells before ART initiation to estimate future levels of “residual” viremia and develop a predictive model.Subjects and Methods. 74 naive patients with HIV infection were enrolled in the study. The HIV reservoir, VL and CD4, CD8 counts were tested before ART initiation and then every 6 months. The patients were followed up for 12 months. Discriminant analysis was used.Results. After 12 months of ART, 69/74 (93.2%) patients had undetectable VL including 14 patients with residual viremia (RV) and 55 in whom no virus was detected. The probability of persisting RV after 12 months of ART was assessed first by one factor – VL prior to ART, after that by three factors – VL, HIV reservoir (HIV DNA), CD8 count prior to ART. A predictive model formula was generated using those factors: D = -5.288-0.001 CD8+1.342VL+0.08 HIV DNA. With discriminant function D>0.065, the patient has a high probability of RV after 12 months of ART; with D ≤0.065, the probability of RV is low. This prognosis should be taken into account when choosing an ART regimen ensuring its maximum optimization.


  • Open Access

    Genetic Aspects of Mycobacterium Tuberculosis Resistance to New Anti-Tuberculosis Drugs

    by A. V. Kukurika, E. I. Veselova, A. B. Peregudova

    We analyzed 57 publications devoted to study of genetic mechanisms of formation of drug resistance of Mycobacterium tuberculosis to bedaquiline, delamanid, pretomanid, linezolid, and clofazimine. Identification of genetic factors of MTB drug resistance make the basis to search for new targets in development of anti-tuberculosis drugs and methods for drug susceptibility testing.


  • Open Access

    Safety of chemotherapy of MDR/XDR-TB patients in high HIV prevalence settings

    by A. V. Kukurika, E. I. Veselova, L. E. Parolina, O. V. Lovacheva

    Безопасность химиотерапии у больных МЛУ/ШЛУ-ТБ в условиях широкой распространенности ВИЧ-инфекции


  • Open Access

    TREC and KREC as prognostic markers of HIV infection and COVID-19

    by E. I. Veselova, O. V. Lovacheva, А. G. Samoylova, D. А. Kudlay, G. D. Kaminskiy

    In some infectious diseases, the number of T- and B-lymphocytes is significantly reduced which is associated with a high risk of the disease progression. The article reviews the effect of two RNA-containing viruses on the specific immune system: SARS-CoV-2 and HIV, as well as parameters of T- and B-cell neogenesis of TREC and KREC, which are markers of immunological disorders and can be used for prognosis for these infections.

  • Efficacy and safety of antiretroviral therapy in «naive» patients with late stage of HIV infection

    by Veselova E.I. Veselova, Karamov E.V. Karamov, Kudlay D.A. Kudlay, Samoilova A.G. Samoilova, Kaminsky G.D. Kaminsky, I.M. Sechenov First Moscow State Medical University of the Ministry of Healthcare of Russia (Sechenov University